Anne B Newman1, Jason L Sanders2, Jorge R Kizer3, Robert M Boudreau4, Michelle C Odden5, Adina Zeki Al Hazzouri6, Alice M Arnold7. 1. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA newmana@edc.pitt.edu. 2. Harvard Affiliated Emergency Medicine Residency, Massachusetts General Hospital, and Brigham and Women's Hospital Department of Emergency Medicine, Boston, MA, USA. 3. Albert Einstein College of Medicine, Jack and Pearl Resnick Campus, Bronx, NY, USA. 4. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 5. Department of Epidemiology, Oregon State University, Corvallis, OR, USA. 6. Department of Epidemiology, University of Miami, Miami, FL, USA. 7. Collaborative Health Studies Coordinating Center, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Multimorbidity is a major driver of physical and cognitive impairment, but rates of decline are also related to ageing. We sought to determine trajectories of decline in a large cohort by disease status, and examined their correspondence with biomarkers of ageing processes including growth hormone, sex steroid, inflammation, visceral adiposity and kidney function pathways. METHODS: We have followed the 5888 participants in the Cardiovascular Health Study (CHS) for healthy ageing and longevity since 1989-90. Gait speed, grip strength, modified mini-mental status examination (3MSE) and the digit symbol substitution test (DSST) were assessed annually to 1998-99 and again in 2005-06. Insulin-like growth hormone (IGF-1), dehydroepiandrosterone sulphate (DHEAS), interleukin-6 (IL-6), adiponectin and cystatin-C were assessed 3-5 times from stored samples. Health status was updated annually and dichotomized as healthy vs not healthy. Trajectories for each function measure and biomarker were estimated using generalized estimating equations as a function of age and health status using standardized values. RESULTS: Trajectories of functional decline showed strong age acceleration late in life in healthy older men and women as well as in chronically ill older adults. Adiponectin, IL-6 and cystatin-C tracked with functional decline in all domains; cystatin-C was consistently associated with functional declines independent of other biomarkers. DHEAS was independently associated with grip strength and IL-6 with grip strength and gait speed trajectories. CONCLUSIONS: Functional decline in late life appears to mark a fundamental ageing process in that it occurred and was accelerated in late life regardless of health status. Cystatin C was most consistently associated with these functional declines.
BACKGROUND: Multimorbidity is a major driver of physical and cognitive impairment, but rates of decline are also related to ageing. We sought to determine trajectories of decline in a large cohort by disease status, and examined their correspondence with biomarkers of ageing processes including growth hormone, sex steroid, inflammation, visceral adiposity and kidney function pathways. METHODS: We have followed the 5888 participants in the Cardiovascular Health Study (CHS) for healthy ageing and longevity since 1989-90. Gait speed, grip strength, modified mini-mental status examination (3MSE) and the digit symbol substitution test (DSST) were assessed annually to 1998-99 and again in 2005-06. Insulin-like growth hormone (IGF-1), dehydroepiandrosterone sulphate (DHEAS), interleukin-6 (IL-6), adiponectin and cystatin-C were assessed 3-5 times from stored samples. Health status was updated annually and dichotomized as healthy vs not healthy. Trajectories for each function measure and biomarker were estimated using generalized estimating equations as a function of age and health status using standardized values. RESULTS: Trajectories of functional decline showed strong age acceleration late in life in healthy older men and women as well as in chronically ill older adults. Adiponectin, IL-6 and cystatin-C tracked with functional decline in all domains; cystatin-C was consistently associated with functional declines independent of other biomarkers. DHEAS was independently associated with grip strength and IL-6 with grip strength and gait speed trajectories. CONCLUSIONS: Functional decline in late life appears to mark a fundamental ageing process in that it occurred and was accelerated in late life regardless of health status. Cystatin C was most consistently associated with these functional declines.
Authors: Alexander Bürkle; María Moreno-Villanueva; Jürgen Bernhard; María Blasco; Gerben Zondag; Jan H J Hoeijmakers; Olivier Toussaint; Beatrix Grubeck-Loebenstein; Eugenio Mocchegiani; Sebastiano Collino; Efstathios S Gonos; Ewa Sikora; Daniela Gradinaru; Martijn Dollé; Michel Salmon; Peter Kristensen; Helen R Griffiths; Claude Libert; Tilman Grune; Nicolle Breusing; Andreas Simm; Claudio Franceschi; Miriam Capri; Duncan Talbot; Paola Caiafa; Bertrand Friguet; P Eline Slagboom; Antti Hervonen; Mikko Hurme; Richard Aspinall Journal: Mech Ageing Dev Date: 2015-03-24 Impact factor: 5.432
Authors: Nancy S Jenny; Benjamin French; Alice M Arnold; Elsa S Strotmeyer; Mary Cushman; Paulo H M Chaves; Jingzhong Ding; Linda P Fried; Stephen B Kritchevsky; Dena E Rifkin; Mark J Sarnak; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2012-02-24 Impact factor: 6.053
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Ronenn Roubenoff; Helen Parise; Hélène A Payette; Leslie W Abad; Ralph D'Agostino; Paul F Jacques; Peter W F Wilson; Charles A Dinarello; Tamara B Harris Journal: Am J Med Date: 2003-10-15 Impact factor: 4.965
Authors: Christine K Liu; Asya Lyass; Joseph M Massaro; Ralph B D'Agostino; Caroline S Fox; Joanne M Murabito Journal: J Gerontol A Biol Sci Med Sci Date: 2013-08-02 Impact factor: 6.053
Authors: Anne B Newman; Alice M Arnold; Barbara L Naydeck; Linda P Fried; Gregory L Burke; Paul Enright; John Gottdiener; Calvin Hirsch; Daniel O'Leary; Russell Tracy Journal: Arch Intern Med Date: 2003-10-27
Authors: Matthew D L O'Connell; Megan M Marron; Robert M Boudreau; Mark Canney; Jason L Sanders; Rose Anne Kenny; Stephen B Kritchevsky; Tamara B Harris; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2019-04-23 Impact factor: 6.053
Authors: Amal A Wanigatunga; Ravi Varadhan; Eleanor M Simonsick; Olga D Carlson; Stephanie Studenski; Luigi Ferrucci; Jennifer A Schrack Journal: J Gerontol A Biol Sci Med Sci Date: 2019-04-23 Impact factor: 6.053
Authors: Christina H Liu; Natalie D Abrams; Danielle M Carrick; Preethi Chander; Johanna Dwyer; Michelle R J Hamlet; Francesca Macchiarini; Mercy PrabhuDas; Grace L Shen; Pushpa Tandon; Merriline M Vedamony Journal: Nat Immunol Date: 2017-10-18 Impact factor: 25.606
Authors: Christa A Hammond; Natalie J Blades; Sarwat I Chaudhry; John A Dodson; W T Longstreth; Susan R Heckbert; Bruce M Psaty; Alice M Arnold; Sascha Dublin; Colleen M Sitlani; Julius M Gardin; Stephen M Thielke; Michael G Nanna; Rebecca F Gottesman; Anne B Newman; Evan L Thacker Journal: Circ Heart Fail Date: 2018-03 Impact factor: 8.790
Authors: Joshua F Baker; Anne B Newman; Alka Kanaya; Mary B Leonard; Babette Zemel; Iva Miljkovic; Jin Long; David Weber; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-16 Impact factor: 6.053
Authors: Jatupol Kositsawat; Chia-Ling Kuo; Lisa C Barry; David Melzer; Stefania Bandinelli; Luigi Ferrucci; Rong Wu; George A Kuchel Journal: J Gerontol A Biol Sci Med Sci Date: 2020-05-22 Impact factor: 6.053
Authors: Daniel Parker; Richard Sloane; Carl F Pieper; Katherine S Hall; Virginia B Kraus; William E Kraus; Janet L Huebner; Olga R Ilkayeva; James R Bain; L Kristin Newby; Harvey Jay Cohen; Miriam C Morey Journal: J Gerontol A Biol Sci Med Sci Date: 2019-02-15 Impact factor: 6.053